About GSK

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. 

  • £30.2bn

    turnover in 2017

  • 3

    global businesses

  • 300

    years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals

Immune system T-cells attacking a cancer cell

Vaccines

Herpes zoster virus of shingles

Consumer Healthcare

Novamin, a key technology in Sensodyne Repair and Protect

How we do it

Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.9bn

    R&D investment in 2017

  • 3

    major launches in 2017 – Shingrix, a vaccine for shingles, Trelegy Ellipta for COPD and Juluca for HIV

  • £6.7bn

    new product sales in Pharmaceuticals and Vaccines in 2017

  • 13%

    Consumer Healthcare sales in 2017 from product innovations launched over the past three years

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • £30.2bn

    total turnover in 2017

  • £8.6bn

    adjusted operating profit in 2017

  • £3.4bn

    free cash flow in 2017

  • £3.9bn

    dividends paid in 2017

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 

  • 85%

    of employees proud to work at GSK

  • £261.6m

    donated in 2017 to local communities through product donations, time and cash

  • 1st

    in Access to Medicines Index all 5 times since its launch in 2008

Key figures

Please refer to our quarterly results materials for further information on GSK’s financial performance.

Our geographies

  • £11.3bn (37.3%)

    US (+6% CER) sales turnover 2017

  • £7.9bn (26.3%)

    Europe (flat CER) sales turnover 2017

  • £11.0bn (36.4%)

    International (+3% CER) sales turnover 2017